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Abstract
IMPORTANCE Although overall rates of opioid use have been plateauing, coprescriptions of
benzodiazepines and opioids have increased greatly in recent years. It is unknown whether this
combination is an independent risk factor for all-cause mortality as opposed to being more
frequently used by persons with a baseline elevated risk of death.
OBJECTIVE To evaluate whether benzodiazepine use, with or without opioid use, is associated with
increased all-cause mortality relative to the use of low-risk antidepressants.
DESIGN, SETTING, AND PARTICIPANTS This retrospective cohort study used a large, nationally
representative US data set (the National Health and Nutrition Examination Surveys [NHANES]) from
1999 to 2015. Eight cycles of NHANES data were used, spanning 37 610 person-years of follow-up
time among 5212 individuals. Statistical analysis was performed from August 24, 2019, through May
23, 2020.
EXPOSURES The primary exposure variable was benzodiazepine and opioid coprescriptions.
Individuals taking selective serotonin reuptake inhibitors (SSRIs) served as an active comparator
reference group.
MAIN OUTCOMES AND MEASURES All-cause mortality was obtained via linkage of NHANES to the
National Death Index. Propensity scores were calculated from covariates associated with
sociodemographic factors, comorbidities, and medication use for more than 1000 prescription
types. Propensity score–weighted mortality hazards were calculated from Cox proportional hazards
regression models.
RESULTS Of 5212 participants aged 20 years or older (1993 men [38.2%]; mean [SD] age, 54.8 [16.9]
years) followed up for a median of 6.7 years (range, 0.2-16.8 years), 101 deaths (33.0 per 1000
person-years) occurred among those receiving cotreatment, 236 deaths (26.5 per 1000
person-years) occurred among those receiving only benzodiazepines, and 227 deaths (20.2 per 1000
person-years) occurred among SSRI recipients taking neither opioids nor benzodiazepines. After
propensity score weighting, a significant increase in all-cause mortality was associated with
benzodiazepine and opioid cotreatment (hazard ratio, 2.04 [95% CI, 1.65-2.52]) and
benzodiazepines without opioids (hazard ratio, 1.60 [95% CI, 1.33-1.92]). Subgroup analyses revealed
an increased risk of mortality for individuals receiving cotreatment who were 65 years or younger
but not for those older than 65 years; similar findings were observed for those receiving
benzodiazepines without opioids.
CONCLUSIONS AND RELEVANCE This study found a significant increase in all-cause mortality
associated with benzodiazepine use with or without opioid use in comparison with SSRI use.
(continued)
Key Points
Question Is benzodiazepine use, with
or without opioid use, an independent
risk factor for all-cause mortality or a
marker for underlying conditions
associated with death?
Findings In this cohort study of 5212
individuals from a large, nationally
representative data set, it was found
that benzodiazepine use, with or
without opioid use, was associated with
a doubling in all-cause mortality risk in
comparison with the use of low-risk
antidepressants. These findings
persisted even after adjustment for
sociodemographic variables and
comorbidity burden.
Meaning This study suggests that
benzodiazepine and opioid cotreatment
may confer an increased long-term
mortality risk; targeted interventions are
needed to decrease overprescribing.
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Abstract (continued)
Benzodiazepine and opioid cotreatment, in particular, was associated with a 2-fold increase in
all-cause mortality even after taking into account medical comorbidities and polypharmacy burden.
JAMA Network Open. 2020;3(12):e2028557. doi:10.1001/jamanetworkopen.2020.28557
Introduction
Benzodiazepines are among the most widely used medications worldwide and are prescribed for
common problems such as anxiety and insomnia.1-3 Up to 13% of US adults have reported
benzodiazepine use in the last year,4 with ambulatory benzodiazepine prescriptions more than
doubling in the last decade.5
Increasing benzodiazepine prescriptions have clinical relevance amid declining life expectancies
and a global epidemic of opioid overdoses. When benzodiazepines are taken alone, long-term use is
associated with falls, cognitive impairment, and life-threatening withdrawal.1,3 When taken together
with opioids, benzodiazepines can further suppress breathing, a common cause of death from opioid
overdose.1,6,7 The danger of benzodiazepine-opioid cotreatment is thus a timely issue, as 20% to
30% of all benzodiazepine recipients in the US are estimated to have an opioid coprescription8 and
more than 30% of opioid overdose deaths are found to involve benzodiazepines.9-11 Despite a recent
plateau in overall opioid use in the US,8,12,13 benzodiazepine-opioid coprescriptions continue to
increase.2,8,14-16 It is tempting to infer elevated mortality risk attributable to benzodiazepines alone
or in combination with opioids, but this topic has proven challenging to study. To date, it is not well
understood if benzodiazepine use—whether with or without opioids—is associated directly with
mortality, as opposed to serving as a marker for unmeasured underlying conditions that are the true
factors associated with excess deaths.
In the case of benzodiazepine use without opioids, data on its long-term mortality risks are
marked by inconsistent findings. Although some studies have found substantial mortality associated
with benzodiazepine use without opioids,17 such that the hazards of taking benzodiazepines more
than 30 times per month were akin to smoking 1 to 2 packs of cigarettes per day,18,19 other studies
have not supported these findings,20 with several analyses suggesting that benzodiazepine-
associated mortality may vary based on age or follow-up time.17,20 Furthermore, these studies have
often been limited to employed, middle-aged populations in commercial insurance databases,20
which may exclude individuals with a heavier comorbidity burden who initiate benzodiazepines.20,21
In the case of benzodiazepine-opioid cotreatment, the literature base is similarly limited.
Although recent data have depicted an increased risk of emergency department visits16 and opioid
overdose deaths in patients with such coprescriptions,22,23 these findings have often been limited to
patients surviving opioid overdoses,16 subpopulations such as veterans,24 and short-term
follow-up.16,24
Our study addresses the existing research gap by evaluating the association of benzodiazepine
use with or without opioid coprescriptions with long-term all-cause mortality using a large nationally
representative data set in the US linked to the National Death Index (NDI), spanning approximately 15
years of follow-up time (1999-2015).
Methods
We used the publicly available National Health and Nutrition Examination Surveys (NHANES) to
obtain a nationally representative sample of approximately 5000 US participants per 2-year cycle.
The NHANES data were collected from 1999 until 2014, with mortality data extending through 2015.
Face-to-face interviews and physical examinations were conducted in participants’ homes by
interviewers, physicians, and medical technicians (net response rate, 75%), in addition to physical
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examinations conducted in mobile examination centers (net response rate, 70%). Full details on
NHANES are described elsewhere.8,25 As all data were completely deidentified, our analyses did not
require human participants review by the Washington University institutional review board. Consent
was waived because all data were deidentified. The Strengthening the Reporting of Observational
Studies in Epidemiology (STROBE) reporting guideline was followed.
Participants
Eligible participants were aged 20 years or older. The observation window during which death was
ascertained began immediately after individuals were surveyed in the in-home interview. Out of
43 793 respondents who participated in the in-home interview and physical examinations, we
excluded 354 persons who died within 1 year after recruitment to reduce bias arising from
benzodiazepine prescriptions for participants with terminal illness.17 We further excluded individuals
who lacked data on any prescription medications (n = 24), mobile examinations (n = 2134), and
study covariates (n = 3896) (Figure 1). We also excluded those without prescriptions for selective
serotonin reuptake inhibitors (SSRIs), benzodiazepines, or narcotics (n = 32 173). Our final analytic
sample of 5212 individuals was linked to the NDI, which contains data on date and underlying cause
for more than 99% of all US deaths,26-28 with a sensitivity and specificity both estimated to be
greater than 97%.29 Linked mortality data extend from January 1, 1999, until time of death or
censorship at December 31, 2015, whichever occurred first. If no match was found with the NDI,
participants were assumed to be alive as of that date.
Ascertainment of Medication Use Data
Data were collected by NHANES on prescription medications taken, spanning both short-term and
long-term prescriptions. Participants were required to show examiners the containers of all
medications used in the last month. The percentage of respondents who provided physical evidence
of medication use ranged from 77.7% (11 512 of 14 817) in the 2009-2010 cycle to 94.5% (13 252 of
14 019) in the 2013-2014 cycle, with medication use ascertained via self-report for the remaining
individuals who could not produce prescription bottles. Of 43 793 respondents participating in
in-home interviews, fewer than 0.05% (n = 24) were missing prescription medication data or
refused to answer.12 Medication data were limited to prescriptions for 30 days or more to exclude
short-term medications for acute medical issues.12
Medication use was matched to Lexicon Plus by NHANES, which used Cerner Multum Inc to
classify medications by therapeutic medication categories.8,12 We tabulated 23 total
benzodiazepines, encompassing short-acting agents, long-acting medications, and selective
benzodiazepine receptor modulators (“Z-drugs” [eg, zolpidem]). Based on established methods in
previous studies,8,12 opioid narcotics included more than 60 generic and brand-name prescription
pain medications12 (full classification scheme details in eTable 1 in the Supplement). Because
Figure 1. Study Inclusion and Exclusion Flowchart
43 793 Respondents (aged >20 y) participating in in-home interview (NHANES 1999-2014)
38 581 Excluded
2134 Did not participate in mobile examination interviews
24 Missing prescription medication data or refused to answer
3896 Missing data on other covariates (medical comorbidities,
alcohol, smoking, blood pressure, and health care use)
354 Died within 1 y of follow-up
32 173 Were not taking SSRIs, benzodiazepines, or opioids
5212 Observations at baseline NHANES survey, with 1:1 linkage with the National Death Index
468 Benzodiazepines and opioids
1256 Benzodiazepines only
1955 Opioids only
1533 Active comparator (SSRIs only, no benzodiazepines or opioids)
Derivation of the study cohort during follow-up, with
1:1 linkage to the National Death Index. We excluded
those who did not participate in mobile examination
interviews, were missing medication data or refused to
answer, or were missing data on other covariates
included in our propensity scores. We also excluded
those who died within 1 year of follow-up or were not
taking selective serotonin reuptake inhibitors (SSRIs),
benzodiazepines, or opioids. NHANES indicates
National Health and Nutrition Examination Surveys.
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selective benzodiazepine receptor modulators have been found to share similar adverse effects as
benzodiazepines,30 benzodiazepines and benzodiazepine receptor modulators were grouped
together.
Covariates and Confounders
To account for confounding medical and psychiatric comorbidities that may be associated with
increased mortality in the population of individuals receiving benzodiazepines, we developed
propensity score weights based on the estimated probability of benzodiazepine prescription status,
using covariates found to be prevalent among persons receiving benzodiazepines3; these covariates
spanned sociodemographic factors, health care use variables, psychiatric comorbidities, and
medication use data for more than 1000 unique prescriptions. Full details are described in the
eMethods in the Supplement.
To increase overlap of measured characteristics between benzodiazepine-opioid users and
nonusers, we used an active comparator group of participants who were not taking benzodiazepines
or opioids and had an active prescription for SSRIs. This is a validated approach taken to address
unobserved confounding factors given SSRIs’ overlapping indications with benzodiazepines without
any known association with all-cause mortality in adults.20,31 We selected SSRIs as our active
comparator rather than non-SSRI antidepressants owing to substantial heterogeneity in non-SSRIs’
indications for use in comparison with benzodiazepines (ie, tricyclic antidepressants for headache
and serotonin norepinephrine reuptake inhibitors for neuropathic pain)20 as well as increased
morbidity and mortality associated with monoamine oxidase inhibitors and tricyclic
antidepressants.32
Statistical Analysis and Sensitivity Analyses
Statistical analysis was performed from August 24, 2019, through May 23, 2020. We calculated the
overall rate of all-cause mortality per 1000 person-years, stratified by follow-up time (<50th
percentile vs 50th percentile of follow-up time) and age (20-65 vs 65 years). We used the Cox
proportional hazards regression model to estimate crude mortality hazards in comparing the active
comparator group with exposure groups 1 and 2. Adjusted mortality hazards were then obtained
after applying propensity score weighting, with SE estimates calculated via bootstrapping with 1000
replications (with a single imputation used within each sampling) to adjust for additional sources of
variability introduced by the propensity score weighting process as well as multiple imputation. As
previously described,8 NHANES reporting guidelines consider estimates to be statistically reliable
with a sample size of more than 420.
To further evaluate robustness of our findings, we conducted stratified analyses by follow-up
time (<50th percentile vs 50th percentile of follow-up time) and age (20-65 vs 65 years).
Because NHANES does not provide data on temporality of health conditions and medications, we
developed an alternative propensity score with more than 650 non–central nervous system (CNS)
medications excluded (ie, cardiovascular, metabolic, and anti-infective medications) and repeated all
analyses after limiting medications in our propensity scores to only those used to treat chronic CNS
disorders. All analyses were performed using SAS, version 4.2 (SAS Institute Inc). All P values were
from 2-sided tests and results were deemed statistically significant at P < .05.
Results
Sample Characteristics
Our sample consisted of 5212 participants (1993 men [38.2%]; mean [SD] age, 54.8 [16.9] years;
3308 White [63.5%]), with baseline characteristics depicted in Table 1. Of all participants, 468
(9.0%) were prescribed both opioids and benzodiazepines, 1256 (24.1%) were prescribed
benzodiazepines only, and 1955 (37.5%) were prescribed opioids only. A total of 1533 individuals
(29.4%) had a prescription for neither opioids nor benzodiazepines but were taking SSRIs. In
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Table 1. Baseline Characteristics of Study Participantsa
Characteristic























Age, mean (SD), y 54.8 (16.9) 56.1 (14.0) 57.9 (16.7) 53.5 (17.1) 53.8 (17.1) .02 <.001 .18
Aged 60-70 y 1058 (20.3) 103 (22.0) 241 (19.2) 421 (21.5) 293 (19.1) .17 .96 .08
Male 1993 (38.2) 171 (36.5) 463 (36.9) 876 (44.8) 483 (31.5) .04 .003 <.001
College graduate 900 (17.3) 49 (10.5) 235 (18.7) 262 (13.4) 354 (23.1) <.001 .005 <.001
Poverty to income ratio
1-2 1353 (26.0) 140 (29.9) 329 (26.2) 530 (27.1) 354 (23.1) .005 .06 .008
>2 2402 (46.1) 159 (34.0) 616 (49.0) 790 (40.4) 837 (54.6) <.001 .002 <.001
White 3308 (63.5) 322 (68.8) 859 (68.4) 1055 (54.0) 1072 (69.9) .64 .38 <.001
Partnered 2990 (57.4) 251 (53.6) 702 (55.9) 1131 (57.9) 906 (59.1) .04 .08 .59
Smoking 1427 (27.4) 183 (39.1) 292 (23.2) 611 (31.3) 341 (22.2) <.001 .52 <.001
Hypertension 2228 (42.7) 244 (52.1) 545 (43.4) 797 (40.8) 642 (41.9) <.001 .42 .53
Hyperlipidemia 1502 (28.8) 141 (30.1) 395 (31.4) 502 (25.7) 464 (30.3) .51 .98 .06
Stroke 406 (7.8) 54 (11.5) 95 (7.6) 131 (6.7) 126 (8.2) .03 .53 .09
Myocardial infarction 429 (8.2) 50 (10.7) 112 (8.9) 149 (7.6) 118 (7.7) .04 .24 .93
Diabetes 953 (18.3) 93 (19.9) 205 (16.3) 391 (20.0) 264 (17.2) .19 .47 .04
Congestive heart failure 356 (6.8) 44 (9.4) 89 (7.1) 127 (6.5) 96 (6.3) .02 .38 .78
Pulmonary disease 1486 (28.5) 183 (39.1) 330 (26.3) 551 (28.2) 422 (27.5) <.001 .54 .65
Liver disease 353 (6.8) 47 (10.0) 80 (6.4) 139 (7.1) 87 (5.7) <.001 .44 .09
Arthritis 2665 (51.1) 337 (72.0) 567 (45.1) 1126 (57.6) 635 (41.4) <.001 .06 <.001
Kidney disease 286 (5.1) 36 (7.7) 68 (5.4) 122 (6.2) 60 (3.9) <.001 .06 .002
Cancer 779 (14.9) 99 (21.2) 221 (17.6) 276 (14.1) 183 (12.0) <.001 <.001 .06
Regular drinking 1290 (24.8) 83 (17.7) 330 (26.3) 446 (22.8) 431 (28.1) <.001 .28 <.001
Antimicrobial drugs 582 (11.2) 71 (15.2) 102 (8.1) 294 (15.0) 110 (7.2) <.001 .19 <.001
Hormonal agents 1218 (23.4) 129 (27.6) 337 (26.8) 357 (18.3) 395 (25.8) .44 .53 <.001
Anticonvulsants 580 (11.1) 104 (22.2) 127 (10.1) 233 (11.9) 116 (7.6) <.001 .02 <.001
Any analgesics 1124 (21.6) 126 (26.9) 236 (18.8) 509 (26.0) 253 (16.5) <.001 .11 <.001
Muscle relaxants 532 (10.2) 114 (24.4) 68 (5.4) 299 (15.3) 51 (3.3) <.001 .007 <.001
Gastrointestinal agents 1512 (29.0) 201 (43.0) 381 (30.3) 534 (27.3) 396 (25.8) <.001 .008 .33
Cardiac or metabolic
medications
2983 (57.2) 315 (67.3) 782 (62.3) 1025 (52.4) 861 (56.2) <.001 .001 .03
Respiratory medications or
antihistamines
1056 (20.3) 154 (32.9) 234 (18.6) 395 (20.2) 273 (17.8) <.001 .57 .07
>2 CNS medications 1070 (20.5) 186 (39.7) 250 (19.9) 435 (22.3) 199 (13.0) <.001 <.001 <.001
<5 Non-CNS medications 993 (19.1) 97 (20.7) 263 (20.9) 333 (17.0) 300 (19.6) .58 .37 .05
Antidepressants (SNRIs,
MAOIs, or TCAs)
396 (7.6) 84 (18.0) 130 (10.4) 142 (7.3) 40 (2.6) <.001 <.001 <.001
Other antidepressants 510 (9.8) 69 (14.7) 153 (12.2) 131 (6.7) 157 (10.2) .007 .10 <.001
Antipsychotics 280 (5.4) 34 (7.3) 102 (8.1) 39 (2.0) 105 (6.9) .76 .20 <.001
Any hospitalization in <1 y 1267 (24.3) 159 (34.0) 299 (23.8) 531 (27.2) 278 (18.1) <.001 <.001 <.001
Any psychiatric visit in <1 y 1125 (21.6) 129 (27.6) 351 (27.9) 217 (11.1) 428 (27.9) .88 .97 <.001
Good current health 3073 (59.0) 181 (38.7) 785 (62.5) 1045 (53.5) 1062 (69.3) <.001 <.001 <.001
Require special health
equipment
1154 (22.1) 173 (37.0) 202 (16.1) 540 (27.6) 239 (15.6) <.001 .72 <.001
Disabled 2096 (40.2) 311 (66.5) 453 (36.1) 885 (45.3) 447 (29.2) <.001 <.001 <.001
Regular ED care 113 (2.2) 11 (2.4) 17 (1.4) 69 (3.5) 16 (1.0) .04 .46 <.001
Worsening health 1148 (22.0) 155 (33.1) 269 (21.4) 495 (25.3) 229 (14.9) <.001 <.001 <.001
>2 Overnight hospitalizations
in <1 y
444 (8.5) 64 (13.7) 100 (8.0) 181 (9.3) 99 (6.5) <.001 .12 .003
Abbreviations: BZD, benzodiazepine; CNS, central nervous system; ED, emergency
department; MAOI, monoamine oxidase inhibitor; SNRI, serotonin norepinephrine
reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor; TCA, tricyclic
antidepressant.
a Two-sided P values show results of univariate comparisons between participants
taking neither BZDs nor opioids (active comparator: SSRIs) and those taking BZDs plus
opioids, BZDs only, and opioids only. Categorical variables were tested with the χ2 test.
Continuous variables were tested with the Wilcoxon rank sum test.
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comparison with the SSRI group, those receiving benzodiazepine-opioid coprescriptions tended to
be older (mean [SD] age, 56.1 [14.0] vs 53.8 [17.1] years), be male (171 [36.5%] vs 483 [31.5%]), and
have a lower income (poverty to income ratio >2, 159 [34.0%] vs 837 [54.6%]), with a higher
prevalence of smoking (183 [39.1%] vs 341 [22.2%]), disability (311 [66.5%] vs 447 [29.2%]),
worsening health (155 [33.1%] vs 229 [14.9%]), hospitalization in the last year (159 [34.0%] vs 278
[18.1%]), and prescription medication use across both CNS and non-CNS medications, paralleling a
higher prevalence of these characteristics in absolute standardized differences seen in eTable 2 in the
Supplement. We used an absolute standardized difference of less than 0.1 to denote negligible
difference in covariate balance between groups20,33 (eTable 2A, 2B, 2C, 2D, and 2E in the
Supplement).
Survival Analysis
The median time to death or censoring was 6.7 years (range, 0.2-16.8 years) for all participants
(eTable 3 in the Supplement). A total of 1423 of 5212 participants (27.3%) had follow-up times
exceeding 10 years, with 37 610 person-years of follow-up time among all participants. Of 892 deaths
that occurred in total (23.7 events per 1000 person-years), 101 (33.0 per 1000 person-years)
occurred among those receiving cotreatment, 236 (26.5 per 1000 person-years) occurred among
those using only benzodiazepines, 328 (22.8 per 1000 person-years) occurred among those using
only opioids, and 227 (20.2 per 1000 person-years) occurred in the active comparator group of SSRI
recipients taking neither benzodiazepines nor opioids (eTable 3 in the Supplement).
Figure 2 illustrates unadjusted Kaplan-Meier curves for survival probability at the start of
follow-up, for which unadjusted log-rank tests showed that all-cause mortality was significantly
elevated in the benzodiazepine-opioid cotreatment group in comparison with those taking
benzodiazepines only, opioids only, and SSRI recipients taking neither (χ2 = 22.41; P < .001). Among
those who were 65 years or younger, we calculated an event rate of 10.3 per 1000 person-years in
comparison with 59.9 per 1000 person-years among their peers older than 65 years (eTable 3 in the
Supplement).
In unadjusted Cox proportional hazards regression models, patients receiving benzodiazepines,
both with and without opioids, exhibited an elevated risk of death compared with SSRI recipients
receiving neither opioids nor benzodiazepines (cotreatment group: hazard ratio [HR], 1.71 [95% CI,
1.34-2.19]; benzodiazepines without opioids group: HR, 1.36 [95% CI, 1.13-1.64]) (Table 2). After
propensity score weighting, hazards of death remained elevated in those receiving cotreatment (HR,
2.04 [95% CI, 1.65-2.52]). A smaller but nonetheless significant increase in all-cause mortality was





























































Kaplan-Meier curves of survival probability stratified
by benzodiazepines (BZDs) plus opioids, BZDs only,
opioids only, and neither BZDs nor opioids (active
comparator, selective serotonin reuptake inhibitors
[SSRIs]). We excluded all participants who died within
1 year of follow-up.
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associated with benzodiazepine use without opioids in adjusted analyses (HR, 1.60 [95% CI,
1.33-1.92]).
Subgroup and Sensitivity Analyses
We observed an increased risk of mortality associated with benzodiazepine-opioid coprescriptions
among younger but not older participants (adjusted HR, 3.27 [95% CI, 2.40-4.47] vs 1.21 [95% CI,
0.86-1.70]), with similar findings among those receiving benzodiazepines without opioids (adjusted
HR, 1.81 [95% CI, 1.29-2.54] vs 0.84 [95% CI, 0.67-1.05]) (Table 2). Among those older than 65 years
in age-stratified analyses, we consistently observed no increased risk of death associated with
cotreatment across all adjusted comparisons. Analyses were also repeated across participants of
different follow-up periods, using the 50th percentile as a threshold between short-term and long-
term follow-up strata. Among those receiving benzodiazepines without opioids, weighted analyses
showed an increased risk of death in those with longer (50th percentile) but not shorter follow-up
times (HR, 2.17 [95% CI, 1.59-2.98] vs 1.17 [95% CI, 0.92-1.50]). Weighted analyses showed similarly
elevated hazards of death among those receiving benzodiazepine and opioid cotreatment regardless
of follow-up time (<50th percentile: HR, 1.35 [95% CI, 1.04-1.76] vs 50th percentile: HR, 1.93 [95%
CI, 1.29-2.88]).
In further sensitivity analyses, we calculated propensity scores that excluded non-CNS agents,
with largely similar effect sizes across all comparisons (eTable 4 in the Supplement). In addition, we
conducted a sensitivity analysis that included participants who survived fewer than 12 months after
recruitment, with similar findings as in our analyses that excluded those who died within 1 year
(eTable 5 in the Supplement).
Discussion
This study illustrates that benzodiazepines, both by themselves and in combination with opioids,
significantly increase the risk of all-cause mortality in comparison with SSRIs alone. In particular, the
benzodiazepine-opioid coprescription group continued to show a nearly 2-fold increase in all-cause
mortality even after taking into account medical comorbidities and polypharmacy burden in adjusted
analyses.
Table 2. Risk of All-Cause Mortality Associated With BZD With or Without Opioids in Unadjusted
and Propensity Score–Weighted Analyses
Characteristic Unweighted HR (95% CI) P value Weighted HR (95% CI) P value
BZDs only vs neither
(active comparator, SSRIs)
All participants 1.36 (1.13-1.64) .001 1.60 (1.33-1.92) <.001
Age, y
20-65 1.52 (1.06-2.18) .02 1.81 (1.29-2.54) <.001
>65 0.86 (0.68-1.07) .17 0.84 (0.67-1.05) .12
Follow-up time
<50th percentile (6.6 y) 1.03 (0.82-1.31) .79 1.17 (0.92-1.50) .21
≥50th percentile (6.6 y) 1.81 (1.31-2.50) <.001 2.17 (1.59-2.98) <.001
BZDs plus opioids vs neither
(active comparator, SSRIs)
All participants 1.71 (1.34-2.19) <.001 2.04 (1.65-2.52) <.001
Age, y
20-65 2.66 (1.77-4.00) <.001 3.27 (2.40-4.47) <.001
>65 1.10 (0.80-1.51) .55 1.21 (0.86-1.70) .28
Follow-up time
<50th percentile (6.6 y) 1.21 (0.90-1.63) .20 1.35 (1.04-1.76) .02
≥50th percentile (6.6 y) 1.73 (1.09-2.75) .02 1.93 (1.29-2.88) .002
Abbreviations: BZD, benzodiazepine; HR, hazard ratio;
SSRI, selective serotonin reuptake inhibitor.
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Although benzodiazepines without opioids were associated with an overall increase in all-cause
mortality in weighted analyses, these hazards of death were negligible among those with shorter as
opposed to longer amounts of follow-up time. This finding may be consistent with existing
literature20 suggesting that benzodiazepine use without opioids is more of a proxy for elevated
short-term mortality risk than a factor directly associated with death. Furthermore, recent findings—
focusing largely on acute as opposed to chronic benzodiazepine and opioid exposures—have
suggested that fatalities associated with pure benzodiazepine overdose are rare and that the
combination of sedative-hypnotic agents with opioids may be an important and understudied factor
associated with mortality.34
We also conducted age-stratified analysis to clarify the burden of psychotropic medications in
the elderly, particularly since earlier studies have found that older adults were more likely to receive
benzodiazepines and opioids.2,35,36 Most studies that have identified a positive association between
benzodiazepines and all-cause mortality were conducted in predominantly adult or young adult
populations,16,17,20 which makes the mortality risk associated with benzodiazepine use in older adults
a poorly understood area. We found no evidence of increased all-cause mortality stemming from
benzodiazepine-opioid cotreatment in participants aged 65 years or older, which parallels similar null
findings among elderly patients receiving benzodiazepines without opioids.37 There was a
consistently elevated mortality risk in participants younger than 65 years, which may be associated
with surging drug poisoning–related mortality that disproportionately affects younger US
populations.38
Strengths and Limitations
Our study has some strengths, including its use of an active comparator, which is associated with
partial control for unobserved confounding. We further adjusted for observed confounding using
propensity score weighting. Taken together, these methods adjust for many health behaviors and
comorbidities that may be associated with increased benzodiazepine-associated mortality. This is
particularly useful given concern that benzodiazepine-opioid cotreatment and all-cause mortality
may share common antecedents or outcomes, potentially associated with confounding by indication
and collider bias.17 Another study strength is the generalizability of NHANES data, which contain
demographic groups that are frequently not included in Veterans Affairs data, as well as older
individuals with a higher burden of medical and psychiatric comorbidities not included in insurance
claims data.16,20 Finally, our analysis spans a longer follow-up period, with a median of nearly 7 years,
than similar analyses,16,20 which may explain the elevated death rates observed in our study (26.5
per 1000 person-years) for benzodiazepines without opioids in comparison with the mortality rates
found by Patorno et al37 (12 per 1000 person-years), whose mean follow-up period was 145 to
160 days.
There are also several limitations that need to be considered. First, despite the use of an active
comparator and good propensity score balance achieved, residual confounding cannot be
completely excluded. Furthermore, propensity score weighting does not ensure avoidance of collider
stratification bias. Second, NHANES does not provide data differentiating on indication, duration,
and dosage of benzodiazepine use. Although our study cannot differentiate between individuals
newly initiating benzodiazepines and longer-term users, previous work has not found significant
differences in hazards even after adjusting for higher dosage and prolonged exposure20 or duration
of use.16 Nonetheless, because each participant is only assessed once, it is not possible to assess
changing patterns of benzodiazepine use over time.
Third, we are unable to deduce if medication use and medical comorbidities in NHANES
precisely preceded exposure to benzodiazepines, which is generally an assumption of propensity
score approaches.39 Despite our inability to infer such temporal precedence, we contend that
NHANES medication data serve as a good proxy for unmeasured comorbidities that likely preceded
benzodiazepine exposure. To assess the possibility of overcorrection via inclusion of mediating
JAMA Network Open | Psychiatry Association Between Benzodiazepine Use With or Without Opioid Use and All-Cause Mortality in the US
JAMA Network Open. 2020;3(12):e2028557. doi:10.1001/jamanetworkopen.2020.28557 (Reprinted) December 9, 2020 8/12
Downloaded From: https://jamanetwork.com/ by a Washington University - St Louis User  on 01/03/2021
variables, we developed an alternative propensity score that excluded more than 650 non–CNS-
acting medications that yielded largely similar results to those from our main models.
Fourth, while we were careful to include nearly every psychiatric prescription medication within
our propensity score along with measures of mental health resource use, NHANES does not provide
data on whether participants met criteria for DSM-validated anxiety and depressive disorders, which
are often treated with benzodiazepines and have been found to correlate with increased suicide risk.
Countering this information, use of an active comparator reduces between-group differences in
depression and anxiety that could not be addressed using measured covariates.
Fifth, NDI-linked NHANES data are not yet available for more recent years, limiting the study’s
generalizability. As the opioid epidemic has evolved since 2015, the most current trends warrant
further investigation. Sixth, the public-use NDI does not provide data on overdose or suicide-specific
mortality. Despite this limitation, our focus on all-cause mortality has the advantage of avoiding
misclassification and missing data that can occur in cause-specific mortality analyses. Furthermore,
recent data24 suggest that nearly 90% of benzodiazepine-opioid cotreatment deaths were due to
nonoverdose causes. Future studies will need to differentiate between benzodiazepine use and
misuse while taking into account illicit drug use, which occurs frequently in patients using
benzodiazepines, although preliminary data suggest that only 1.5% of patients with benzodiazepine
prescriptions develop a substance use disorder.21
Conclusions
Our findings suggest that benzodiazepine-opioid cotreatment and use of benzodiazepines without
opioids are associated with long-term all-cause mortality in comparison with individuals who used
low-risk antidepressants. We also found that benzodiazepine use (with or without opioids) was
associated with increased mortality risk only among those 65 years or younger. Amid very few opioid
prescribing guidelines targeting patients receiving sedative-hypnotics, benzodiazepine-opioid
cotreatment poses a therapeutic dilemma for physicians. Concerted efforts by physicians, scientists,
and policymakers are warranted to decrease overprescribing of these medications, identify patients
at elevated risk, and ultimately implement targeted interventions.
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